Evidence map›Paper›PMID 39269583›Full record

ArticleGeroScience2025

Comprehensive analysis of molecular, physiological, and functional biomarkers of aging with neurological diseases using Mendelian randomization.

Yume Imahori, Chenxi Qin, Bowen Tang, Sara Hägg

Abstract read
In one paragraph

Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yume ImahoriThe Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Chenxi QinThe Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Bowen TangThe Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Sara HäggThe Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. sara.hagg@ki.se.ORCID 0000-0002-2452-1500

Funding

Repurposing drugs for Alzheimer´s disease using a reverse translational approachR01AG067996 · NIA · KAROLINSKA INSTITUTE · PI HAGG, SARA · 2024 to 2025
$973k
NIA NIH HHS R01 AG067996NIA NIH HHS R01AG067996Vetenskapsrådet 2022-01608
6 · The paper itself

Abstract

An increasing burden of neurological diseases (NDs) has been a public health challenge in an aging society. Age, especially biological age, is the most important risk factor for NDs. Identification of biomarkers of aging to capture NDs might lead to a better understanding of the underlying mechanisms of pathological brain aging and the implementation of effective intervention. We conducted a comprehensive two-sample Mendelian Randomization (MR) study to investigate the association between various biomarkers of aging and three leading causes of NDs: Alzheimer's disease (AD), vascular dementia (VaD), and ischemic stroke. Publicly available GWAS summary statistics on people from European ancestry were obtained for six molecular biomarkers, two physiological biomarkers, and eight functional biomarkers, and three NDs. Genetic variants serving as instrumental variables (IVs) were identified for each biomarker. The MR analysis included inverse variance weighted (IVW), weighted median, MR-Egger, and MR-PRESSO. We found that short telomere length and decrease in appendicular lean mass were associated with an increased risk for AD (OR IVW = 1.12 per 1SD decrease, 95% confidence interval 1.02-1.22, and OR IVW = 1.11, 1.06-1.16, respectively), whereas high frailty index showed a protective effect for AD. Accelerated BioAge appeared to be associated with increased risk for ischemic stroke (OR IVW = 1.3 per year in BioAge acceleration, 95% CI 1.19-1.41). Our findings implied a causal association of short telomere length and a decrease in appendicular lean mass with an increased risk for AD, while BioAge appeared to be a good biomarker for ischemic stroke. Further studies are needed to validate these associations and explore underlying mechanisms.

Indexed as

AgingAlzheimer DiseaseDementia, VascularIschemic StrokeNervous System DiseasesAgedBiomarkersFemaleGenome-Wide Association StudyHumansMaleMendelian Randomization AnalysisRisk FactorsBiomarkersBiological ageDementiaMendelian randomizationNeurological disease

Identifiers

PMID39269583
PMCPMC12181546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.